Epigenetic Approaches in the Treatment of Myelodysplastic Syndromes: Clinical Utility of Azacitidine

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s5852
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Cost-Effectiveness in Canada of Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndromes

Current Oncology
Oncology
2013English

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Frontiers in Oncology
Cancer ResearchOncology
2019English

ABC of Clinical Haematology: The Myelodysplastic Syndromes

BMJ
1997English

A Comprehensive Overview of the Role of Azacitidine in the Management of Myelodysplastic Syndromes and Acute Myeloid Leukaemia

European Oncology and Haematology
OncologyHematology
2014English

Safety and Efficacy of Azacitidine in the Treatment of Elderly Patients With Myelodysplastic Syndrome

Clinical Interventions in Aging
MedicineGerontologyGeriatrics
2012English

Correction: Mutations in the DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes

Oncotarget
Oncology
2018English

The Myelodysplastic Syndromes

Emerging Cancer Therapeutics
2011English

Evaluation of Azacitidine in Patients With Transplant‑ineligible Myelodysplastic Syndromes and Acute Myeloid Leukemia With Myelodysplasia‑related Changes in a Japanese Clinical Setting

Oncology Letters
Cancer ResearchOncology
2019English

The Myelodysplastic Syndromes

Oncologist
Cancer ResearchMedicineOncology
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy